Cervical Cancer Drugs Market: Rising Demand and Emerging Trends And Future Opportunities Till 2027
Cervical cancer develops in the cervix of women and primarily affects sexually active women aged 30 to 45. Cervical cancer frequently has no symptoms in its early stages. However, the death rate from cervical cancer can be significantly reduced by using the Pap test (Papanicolaou test), a screening procedure that can detect changes in the cervix before cancer develops. Cervical cancer comes in several forms, the most common of which are squamous cell cancer and adenocarcinoma.
Drivers of the Cervical Cancer Drugs Market
The increasing number of drug approvals for the treatment of cervical cancer by the U.S. Food and Drug Administration (FDA) is expected to drive Growth in The Cervical Cancer Drugs Market over the forecast period. For example, in September 2017, the FDA approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple cancers, including cervical, lung, brain, colorectal, and kidney cancer. Mvasi is approved for the treatment of persistent, recurrent, or metastatic cervical cancer. The US Food and Drug Administration approved Genentech's Avastin, a bevacizumab solution for intravenous infusion in combination with paclitaxel for the treatment of persistent, recurrent, or metastatic cervical cancer, in August 2014.
Furthermore, rising insurance coverage and an increase in the number of new targeted cancer drugs are expected to support the revenue growth of the Cervical Cancer Drugs Market. For example, the National Cancer Institute spent approximately $4,480 million in 2015 on cancer research, including cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukaemia, ovarian cancer, and uterine cancer. Furthermore, according to the American Cancer Society, the United States spent approximately US$ 87.8 billion in 2014 on cancer research, with private insurance companies bearing the majority of the cost (approximately 44 percent).
The rising incidence of cervical cancer in the global population, as well as the rise in the incidence of HIV in women and a lack of awareness about the diagnosis and prevention of invasive cancer, are expected to drive the growth of the Cervical Cancer Drugs Market. Furthermore, in March 2018, the American Cancer Society funded approximately 22 grants for cervical cancer, totaling approximately US$ 9.3 million. The funding value is offered to a single or group of research projects that include a specific type of cancer or cancer area. For example, according to Cancer Research UK data from 2015, approximately 3,200 new cervical cancer cases were registered in the UK each year from 2013 to 2015.
Comments
Post a Comment